Los Angeles Capital Management LLC trimmed its position in Kindred Biosciences, Inc. (NASDAQ:KIN) by 4.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 70,953 shares of the biopharmaceutical company’s stock after selling 2,930 shares during the period. Los Angeles Capital Management LLC’s holdings in Kindred Biosciences were worth $306,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the stock. Virtu Financial LLC acquired a new stake in Kindred Biosciences in the 4th quarter worth about $129,000. JPMorgan Chase & Co. boosted its holdings in shares of Kindred Biosciences by 214.8% during the 4th quarter. JPMorgan Chase & Co. now owns 110,887 shares of the biopharmaceutical company’s stock worth $478,000 after purchasing an additional 75,666 shares during the last quarter. Squarepoint Ops LLC acquired a new position in shares of Kindred Biosciences during the 4th quarter worth approximately $68,000. DCF Advisers LLC acquired a new position in shares of Kindred Biosciences during the 4th quarter worth approximately $172,000. Finally, Public Employees Retirement System of Ohio acquired a new position in shares of Kindred Biosciences during the 4th quarter worth approximately $53,000. Institutional investors own 66.31% of the company’s stock.

In related news, major shareholder Park West Asset Management Llc sold 210,472 shares of the business’s stock in a transaction on Thursday, January 28th. The stock was sold at an average price of $5.25, for a total transaction of $1,104,978.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Denise Bevers sold 8,396 shares of the company’s stock in a transaction dated Wednesday, March 17th. The stock was sold at an average price of $5.00, for a total value of $41,980.00. Following the sale, the director now owns 143,835 shares in the company, valued at approximately $719,175. The disclosure for this sale can be found here. Insiders own 12.63% of the company’s stock.

Several brokerages have recently weighed in on KIN. Aegis restated a “buy” rating on shares of Kindred Biosciences in a report on Monday, February 15th. Zacks Investment Research raised shares of Kindred Biosciences from a “sell” rating to a “hold” rating in a research report on Tuesday, March 9th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $9.95.

KIN stock opened at $4.71 on Wednesday. The business’s fifty day moving average price is $4.83 and its 200 day moving average price is $4.51. Kindred Biosciences, Inc. has a 12-month low of $3.20 and a 12-month high of $6.00. The company has a current ratio of 12.71, a quick ratio of 12.64 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $195.22 million, a PE ratio of -6.83 and a beta of 1.19.

Kindred Biosciences (NASDAQ:KIN) last released its earnings results on Monday, March 15th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.01. The company had revenue of $0.95 million during the quarter, compared to the consensus estimate of $0.96 million. Kindred Biosciences had a negative return on equity of 25.42% and a negative net margin of 62.50%. Research analysts predict that Kindred Biosciences, Inc. will post -0.5 EPS for the current fiscal year.

Kindred Biosciences Company Profile

Kindred Biosciences, Inc, a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates.

Featured Story: What are the benefits of momentum investing?

Want to see what other hedge funds are holding KIN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kindred Biosciences, Inc. (NASDAQ:KIN).

Institutional Ownership by Quarter for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.